Citi Upgrades Dimension Therapeutics (DMTX) to Neutral (Yesterday)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Regenxbio (RGNX) Confirms it Will Not Increase Consideration for Dimension Therapeutics (DMTX)
October 2, 2017 8:33 AM EDTREGENXBIO Inc. (Nasdaq: RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq: DMTX) notified REGENXBIO that it has determined that it has received a superior proposal as defined in the merger agreement under which REGENXBIO would have acquired Dimension in an all-stock transaction for an implied value of approximately $3.41 per share based on the closing stock price of REGENXBIO stock on August 24, 2017.
Late yesterday, Dimension notified REGENXBIO that its board of directors determined that the recently amended proposal from Ultragenyx Pharmaceutical Inc. (Nasdaq:... More
